Allopregnanolone in Postpartum Depression.
GABAA receptors
allopregnanolone
brexanolone
neurosteroid-based therapeutics
post-partum depression
rapid-acting antidepressants
Journal
Frontiers in global women's health
ISSN: 2673-5059
Titre abrégé: Front Glob Womens Health
Pays: Switzerland
ID NLM: 101776281
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
11
2021
accepted:
01
02
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Postpartum depression (PPD) is a debilitating psychiatric disorder characterized by a high worldwide prevalence and serious long-term negative outcomes for both mothers and children. The lack of a specific treatment and overreliance on pharmacotherapy with limited efficacy and delayed treatment response has constituted a complication in the management of PPD. Recently, the Food and Drug Administration (FDA) in the USA approved a synthetic formulation of the GABAergic neurosteroid allopregnanolone, administered intravenously (brexanolone) for the rapid, long-lasting and effective treatment of PPD. Hereinafter, we review findings on allopregnanolone biosynthesis and GABA
Identifiants
pubmed: 35558166
doi: 10.3389/fgwh.2022.823616
pmc: PMC9088875
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
823616Informations de copyright
Copyright © 2022 Pinna, Almeida and Davis.
Déclaration de conflit d'intérêts
GP is a paid consultant to PureTech Health (Boston, MA, USA), GABA Therapeutics, and NeuroTrauma Sciences (Alpharetta, GA, USA). He has two patent applications, one on N-palmitoylethanolamine (PEA) and peroxisome proliferator-activated receptor alpha (PPAR-α) agonists US20180369171A1, pending, and one on allopregnanolone analogs US11266663B2 granted on March 8, 2022 in the treatment of neuropsychiatric disorders. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Cell Neurosci. 2017 Aug 29;11:208
pubmed: 28900387
Asian J Psychiatr. 2020 Oct;53:102353
pubmed: 32927309
Br J Pharmacol. 2017 Oct;174(19):3226-3241
pubmed: 28456011
Neurobiol Stress. 2020 May 15;13:100225
pubmed: 32490055
Psychoneuroendocrinology. 2006 May;31(4):485-92
pubmed: 16406349
Am J Psychiatry. 2000 Jun;157(6):924-30
pubmed: 10831472
Neuropsychopharmacology. 2019 Feb;44(3):546-554
pubmed: 30327498
J Neurochem. 2006 Jul;98(1):122-33
pubmed: 16805802
Front Endocrinol (Lausanne). 2011 Nov 21;2:73
pubmed: 22649384
Prog Neurobiol. 2014 Feb;113:106-36
pubmed: 24012715
Lancet. 2017 Jul 29;390(10093):480-489
pubmed: 28619476
Biol Psychiatry. 2006 Oct 1;60(7):704-13
pubmed: 16934764
Psychoneuroendocrinology. 2021 Sep 24;134:105424
pubmed: 34607173
Neurobiol Stress. 2020 Aug 05;13:100246
pubmed: 32875009
CNS Drugs. 2019 Mar;33(3):265-282
pubmed: 30790145
Focus (Am Psychiatr Publ). 2020 Apr;18(2):106-119
pubmed: 33162848
Neuropsychobiology. 2014;69(3):147-53
pubmed: 24776841
Psychopharmacology (Berl). 2014 Sep;231(17):3569-80
pubmed: 24781515
Psychopharmacology (Berl). 2006 Jun;186(3):362-72
pubmed: 16432684
Int J Mol Sci. 2021 Feb 10;22(4):
pubmed: 33578758
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3239-44
pubmed: 9501247
Front Endocrinol (Lausanne). 2020 May 14;11:236
pubmed: 32477260
Neurosci Biobehav Rev. 2019 Oct;105:136-177
pubmed: 30970272
Neurobiol Stress. 2019 Nov 27;12:100203
pubmed: 31879693
Neurobiol Stress. 2019 Oct 24;11:100198
pubmed: 31709278
Lancet. 2018 Sep 22;392(10152):1058-1070
pubmed: 30177236
Psychoneuroendocrinology. 2016 Aug;70:98-107
pubmed: 27209438
Psychol Med. 2018 Nov;48(15):2453-2455
pubmed: 30070192
Curr Psychiatry Rep. 2018 Aug 9;20(9):78
pubmed: 30094520
Neurosci Biobehav Rev. 2013 Jan;37(1):109-22
pubmed: 23085210
F1000Res. 2019 May 29;8:
pubmed: 31275559
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4275-80
pubmed: 16537521
Neuron. 2008 Jul 31;59(2):207-13
pubmed: 18667149
Neurobiol Stress. 2020 Feb 03;12:100212
pubmed: 32435663
Front Behav Neurosci. 2019 Jun 11;13:114
pubmed: 31244621
J Clin Endocrinol Metab. 2000 Jul;85(7):2429-33
pubmed: 10902789
Neurobiol Stress. 2020 Apr 09;12:100218
pubmed: 32435667
Psychoneuroendocrinology. 2017 May;79:116-121
pubmed: 28278440
Prog Neurobiol. 2014 Feb;113:79-87
pubmed: 24215796
JAMA Psychiatry. 2021 Sep 1;78(9):951-959
pubmed: 34190962
J Psychiatr Res. 2018 Sep;104:235-248
pubmed: 30114665
Hum Psychopharmacol. 2017 Mar;32(2):
pubmed: 28370307
Acta Physiol (Oxf). 2015 Mar;213(3):575-85
pubmed: 25529063
Nat Neurosci. 2005 Jun;8(6):797-804
pubmed: 15895085
Psychoneuroendocrinology. 2019 Apr;102:95-104
pubmed: 30529908
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13284-9
pubmed: 9789080
Am J Psychiatry. 1998 Jul;155(7):910-3
pubmed: 9659856
Psychopharmacology (Berl). 2016 Apr;233(7):1299-310
pubmed: 26856852
Obstet Gynecol. 2001 Jan;97(1):77-80
pubmed: 11152912